Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
Stock detail
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
ORIC
ORIC Pharmaceuticals, Inc.
NASDAQGS
Biotechnology
United States
$12.86
▲
+0.12 (+0.94%)
CLOSED
—
OPEN
$13.17
HIGH
$12.99
LOW
$12.51
PREV CLOSE
$12.74
VOLUME
991.4K
0.63x avg
BID / ASK
9.20 / 16.08
spr 6.880
MARKET CAP
$1.33B
DAY RANGE
$12.51
$12.99
P/E (TTM)
—
Fwd -8.0
EPS (TTM)
-1.30
DIV YIELD
—
52W HIGH
$14.93
-13.9%
52W LOW
$7.23
+77.9%
BETA
0.99
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$12.86
+0.00
(+0.00%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
ORIC
$12.86
▲
+0.94%
Chart
Valuation
Financials
Peers
News
ORIC · K 線技術分析（即時、可互動）
basic
pro
快速分析（約 90–120 秒）
K 線圖載入中…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，約 90–120 秒。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
One-Year Trajectory
RISK-ON
251 BARS · +17.1% YOY
1-year price chart. Started at 10.88, currently 12.74, up 17.1 percent. Range 7.47 to 14.65 over 251 data points.
2025-09-05
$10.88 → $12.74 (+17.1%)
2026-09-03
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Peers
Loading § Peers
§ Recent News
Loading § Recent News
EDITORIAL · NOT INVESTMENT ADVICE.
Data sources: Finnhub (quote / profile / news / peers) + Yahoo (stats) + SEC EDGAR XBRL (financials + DCF). All values cached for 5 minutes via ISR.
VALUATION
Deterministic Valuation (SEC EDGAR + Finnhub)
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
$8.36
WACC Used
+7.0%
Terminal g
+3.5%
Verdict: strong-sell
· peers $8.36 (-35.0%)
Peers:
ALT
AS PE30
APTV PE22
ATI PE62
BCE PE5
BMRN PE180
BRKR
CPT PE35
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers.
FINANCIALS
Multi-Year Financials (SEC XBRL)
—
3 FY · NO YOY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
—
-$129.5M
-$111.0M
-$111.7M
$408.9M
2024-12
—
-$127.8M
-$112.7M
-$113.8M
$274.1M
2023-12
—
-$100.7M
-$85.7M
-$86.5M
$252.0M
PEERS
Sector & Industry Peers
CALM
10 PEERS · FINNHUB
ALT
AS
APTV
ATI
BCE
BMRN
BRKR
CPT
CVNA
CRBG
NEWS
Recent News (past 14 days)
CALM
8 HEADLINES · LAST 14 DAYS
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 2026-09-04
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire · 2026-09-02
Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing
MT Newswires · 2026-08-28
Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses?
Simply Wall St. · 2026-08-07
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
GlobeNewswire · 2026-08-03
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
GlobeNewswire · 2026-07-20
ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer
MT Newswires · 2026-07-14
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
GlobeNewswire · 2026-07-14